David Zaccardelli Sells 3,200 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 3,200 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $5.00, for a total value of $16,000.00. Following the transaction, the chief executive officer now owns 15,075,424 shares in the company, valued at approximately $75,377,120. This represents a 0.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

David Zaccardelli also recently made the following trade(s):

• On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total value of $495,428.88.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total value of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total value of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total value of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Trading Down 1.2 %

Shares of NASDAQ VRNA opened at $38.66 on Wednesday. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -20.14 and a beta of 0.46. Verona Pharma plc has a 12-month low of $11.39 and a 12-month high of $40.76. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The stock’s 50 day simple moving average is $35.03 and its 200 day simple moving average is $25.79.

Verona Pharma (NASDAQ:VRNA) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The company had revenue of $5.62 million during the quarter, compared to analyst estimates of $2.31 million. During the same quarter last year, the business posted ($0.18) earnings per share. Equities research analysts expect that Verona Pharma plc will post -2.11 EPS for the current year.

Institutional Trading of Verona Pharma

Hedge funds have recently made changes to their positions in the stock. First Turn Management LLC bought a new stake in shares of Verona Pharma in the 3rd quarter worth approximately $16,483,000. The Manufacturers Life Insurance Company acquired a new stake in Verona Pharma in the 2nd quarter valued at approximately $859,000. Crossmark Global Holdings Inc. acquired a new stake in Verona Pharma in the 3rd quarter valued at approximately $465,000. GSA Capital Partners LLP acquired a new stake in Verona Pharma in the 3rd quarter valued at approximately $849,000. Finally, Rosalind Advisors Inc. increased its position in Verona Pharma by 10.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 275,000 shares of the company’s stock valued at $7,912,000 after acquiring an additional 25,000 shares during the period. Institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on VRNA shares. Truist Financial boosted their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Wells Fargo & Company upped their price objective on Verona Pharma from $50.00 to $64.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group upped their price objective on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright upped their price objective on Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Verona Pharma presently has a consensus rating of “Buy” and a consensus target price of $43.83.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.